{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:43:58Z","timestamp":1789523038471,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T00:00:00Z","timestamp":1722124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021B1515140063"],"award-info":[{"award-number":["2021B1515140063"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2022CFB209"],"award-info":[{"award-number":["2022CFB209"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC1303100"],"award-info":[{"award-number":["2016YFC1303100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2015CB553903"],"award-info":[{"award-number":["2015CB553903"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371541"],"award-info":[{"award-number":["32371541"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171465"],"award-info":[{"award-number":["32171465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102392"],"award-info":[{"award-number":["82102392"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neo.2024.101037","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:41:43Z","timestamp":1723556503000},"page":"101037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Metformin combined with cisplatin reduces anticancer activity via ATM\/CHK2-dependent upregulation of Rad51 pathway in ovarian cancer"],"prefix":"10.1016","volume":"57","author":[{"given":"Jingjing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10177","key":"10.1016\/j.neo.2024.101037_bib0001","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neo.2024.101037_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"4","key":"10.1016\/j.neo.2024.101037_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12040988","article-title":"Surgery in advanced ovary cancer: primary versus interval cytoreduction","volume":"12","author":"Cummings","year":"2022","journal-title":"Diagnostics"},{"issue":"12","key":"10.1016\/j.neo.2024.101037_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126532","article-title":"Ovarian cancer immunotherapy and personalized medicine","volume":"22","author":"Morand","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9990","key":"10.1016\/j.neo.2024.101037_bib0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.neo.2024.101037_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143318","article-title":"The potential of novel lipid agents for the treatment of chemotherapy-resistant human epithelial ovarian cancer","volume":"14","author":"Nachtigal","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2024.101037_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.826716","article-title":"Sporoderm-Broken spores of ganoderma lucidum sensitizes ovarian cancer to cisplatin by ROS\/ERK signaling and attenuates chemotherapy-related toxicity","volume":"13","author":"Cen","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"15","key":"10.1016\/j.neo.2024.101037_bib0008","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.neo.2024.101037_bib0009","doi-asserted-by":"crossref","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum\u2011based chemotherapy resistance in ovarian cancer (Review)","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.neo.2024.101037_bib0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2024.101037_bib0011","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1471-2407-12-200","article-title":"Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy","volume":"12","author":"Gamarra-Luques","year":"2012","journal-title":"BMC Cancer"},{"issue":"144","key":"10.1016\/j.neo.2024.101037_bib0012","first-page":"219","article-title":"New developments in molecular targeted therapy of ovarian cancer","volume":"26","author":"Guan","year":"2018","journal-title":"Discovery Med."},{"issue":"9","key":"10.1016\/j.neo.2024.101037_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002954","article-title":"Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2\/mTORC1\/p62 axis in tumor-infiltrating CD8T lymphocytes","volume":"9","author":"Nishida","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"23","key":"10.1016\/j.neo.2024.101037_bib0014","doi-asserted-by":"crossref","first-page":"13012","DOI":"10.1073\/pnas.1918845117","article-title":"Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1","volume":"117","author":"Xie","year":"2020","journal-title":"Proc. Nat. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.neo.2024.101037_bib0015","article-title":"Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer","volume":"5","author":"Brown","year":"2020","journal-title":"JCI insight"},{"issue":"1","key":"10.1016\/j.neo.2024.101037_bib0016","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1582-4934.2009.00954.x","article-title":"Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner","volume":"15","author":"Rattan","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.neo.2024.101037_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120680","article-title":"Combined regimens of cisplatin and metformin in cancer therapy: a systematic review and meta-analysis","volume":"304","author":"Jafarzadeh","year":"2022","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.neo.2024.101037_bib0018","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cncr.32539","article-title":"Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer","volume":"126","author":"Gulati","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.neo.2024.101037_bib0019","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3892\/or.2013.2862","article-title":"Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation","volume":"31","author":"Quattrini","year":"2014","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.neo.2024.101037_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151890","article-title":"Metformin prevents cisplatin-induced cognitive impairment and brain damage in mice","volume":"11","author":"Zhou","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2024.101037_bib0021","doi-asserted-by":"crossref","first-page":"23975","DOI":"10.1038\/srep23975","article-title":"Metformin protects against cisplatin-induced tubular cell apoptosis and acute kidney injury via AMPK\u0391-regulated autophagy induction","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neo.2024.101037_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.956190","article-title":"Metformin-induced AMPK activation promotes cisplatin resistance through PINK1\/Parkin dependent mitophagy in gastric cancer","volume":"12","author":"Xiao","year":"2022","journal-title":"Front. Oncol."},{"issue":"1-3","key":"10.1016\/j.neo.2024.101037_bib0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejphar.2010.11.005","article-title":"Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt","volume":"651","author":"Janjetovic","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neo.2024.101037_bib0024","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2020.08.002","article-title":"Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma","volume":"491","author":"Liu","year":"2020","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.neo.2024.101037_bib0025","first-page":"1862","article-title":"XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells","volume":"61","author":"Asselin","year":"2001","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.neo.2024.101037_bib0026","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.canlet.2008.08.027","article-title":"Implication of the Akt2\/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells","volume":"273","author":"Weng","year":"2009","journal-title":"Cancer Lett."},{"issue":"22","key":"10.1016\/j.neo.2024.101037_bib0027","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/jnci\/djt302","article-title":"miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition","volume":"105","author":"Sun","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.neo.2024.101037_bib0028","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.cdd.4400476","article-title":"Emerging roles of caspase-3 in apoptosis","volume":"6","author":"Porter","year":"1999","journal-title":"Cell Death Differ."},{"issue":"4","key":"10.1016\/j.neo.2024.101037_bib0029","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.leu.2402090","article-title":"Phosphorylation of Bcl2 and regulation of apoptosis","volume":"15","author":"Ruvolo","year":"2001","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.neo.2024.101037_bib0030","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkn550","article-title":"Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin","volume":"36","author":"Kinner","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"15","key":"10.1016\/j.neo.2024.101037_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158125","article-title":"The molecular mechanisms of actions, effects, and clinical implications of PARP inhibitors in epithelial ovarian cancers: a systematic review","volume":"23","author":"Lau","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neo.2024.101037_bib0032","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-genet-021920-092410","article-title":"RAD51 gene family structure and function","volume":"54","author":"Bonilla","year":"2020","journal-title":"Annu. Rev. Genet."},{"issue":"4","key":"10.1016\/j.neo.2024.101037_bib0033","first-page":"1210","article-title":"Inhibition of apoptosis through AKT-mTOR pathway in ovarian cancer and renal cancer","volume":"15","author":"Chen","year":"2023","journal-title":"Aging"},{"issue":"4","key":"10.1016\/j.neo.2024.101037_bib0034","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/abbs\/gmv128","article-title":"Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges","volume":"48","author":"Yung","year":"2016","journal-title":"Acta Biochim. Biophy. Sin."},{"issue":"9","key":"10.1016\/j.neo.2024.101037_bib0035","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.neo.2024.101037_bib0036","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","article-title":"Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints","volume":"73","author":"Sancar","year":"2004","journal-title":"Annu. Rev. Biochem."},{"issue":"8","key":"10.1016\/j.neo.2024.101037_bib0037","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nature Rev. Endocrinol."},{"issue":"2","key":"10.1016\/j.neo.2024.101037_bib0038","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2008.04.008","article-title":"In vitro metformin anti-neoplastic activity in epithelial ovarian cancer","volume":"110","author":"Gotlieb","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.neo.2024.101037_bib0039","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbrc.2022.12.069","article-title":"Metformin enhances anti-cancer properties of resveratrol in MCF-7 breast cancer cells via induction of apoptosis, autophagy and alteration in cell cycle distribution","volume":"644","author":"Fatehi","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.neo.2024.101037_bib0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2009.12.001","article-title":"ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968","volume":"292","author":"Zuco","year":"2010","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.neo.2024.101037_bib0041","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/bjc.2013.187","article-title":"Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK","volume":"108","author":"Storozhuk","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2024.101037_bib0042","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.biopha.2014.11.021","article-title":"Metformin enhances radiation response of ECa109 cells through activation of ATM and AMPK","volume":"69","author":"Feng","year":"2015","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.neo.2024.101037_bib0043","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bcp.2011.12.022","article-title":"Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics","volume":"83","author":"Yang","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.neo.2024.101037_bib0044","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12935-021-01953-5","article-title":"Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer","volume":"21","author":"Feng","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"10","key":"10.1016\/j.neo.2024.101037_bib0045","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/15384047.2015.1071738","article-title":"Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51","volume":"16","author":"Wang","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"11","key":"10.1016\/j.neo.2024.101037_bib0046","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1592\/phco.30.11.1159","article-title":"Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs","volume":"30","author":"McFarland","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.neo.2024.101037_bib0047","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pcd.2020.06.001","article-title":"Metformin and risk of cancer among patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2021","journal-title":"Primary Care Diabetes"},{"issue":"3","key":"10.1016\/j.neo.2024.101037_bib0048","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.amjms.2017.05.006","article-title":"Metformin has positive therapeutic effects in colon cancer and lung cancer","volume":"354","author":"Henderson","year":"2017","journal-title":"Am. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.neo.2024.101037_bib0049","doi-asserted-by":"crossref","first-page":"12374","DOI":"10.1038\/s41598-022-16677-3","article-title":"The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus","volume":"12","author":"Tarhini","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.neo.2024.101037_bib0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF03345423","article-title":"Does use of metformin protect against cancer in type 2 diabetes mellitus?","volume":"35","author":"Bo","year":"2012","journal-title":"J. Endocrinol. Invest."},{"issue":"5","key":"10.1016\/j.neo.2024.101037_bib0051","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2337\/dci22-0047","article-title":"Metformin and cancer: solutions to a real-world evidence failure","volume":"46","author":"Yu","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.neo.2024.101037_bib0052","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/dc12-0740","article-title":"The use of metformin and the incidence of lung cancer in patients with type 2 diabetes","volume":"36","author":"Smiechowski","year":"2013","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.neo.2024.101037_bib0053","doi-asserted-by":"crossref","first-page":"11703","DOI":"10.1002\/cam4.5545","article-title":"Breast cancer risk for women with diabetes and the impact of metformin: a meta-analysis","volume":"12","author":"Lu","year":"2023","journal-title":"Cancer Med."},{"issue":"14","key":"10.1016\/j.neo.2024.101037_bib0054","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1158\/1078-0432.CCR-20-0269","article-title":"AMPK activation by metformin promotes survival of dormant ER(+) breast cancer cells","volume":"26","author":"Hampsch","year":"2020","journal-title":"Clinical Cancer Res."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:00:35Z","timestamp":1778616035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558624000794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":54,"alternative-id":["S1476558624000794"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2024.101037","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin combined with cisplatin reduces anticancer activity via ATM\/CHK2-dependent upregulation of Rad51 pathway in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2024.101037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101037"}}